Oxford BioDynamics (LON:OBD) Shares Up 16.6% – What’s Next?

Oxford BioDynamics Plc (LON:OBD)’s share price shot up 16.6% on Friday . The stock traded as high as GBX 0.38 ($0.01) and last traded at GBX 0.38 ($0.01). 20,824,066 shares traded hands during mid-day trading, an increase of 16% from the average session volume of 17,970,898 shares. The stock had previously closed at GBX 0.33 ($0.00).

Analyst Upgrades and Downgrades

Separately, Shore Capital restated a “house stock” rating on shares of Oxford BioDynamics in a report on Thursday, March 13th.

Oxford BioDynamics Stock Performance

The stock has a fifty day simple moving average of GBX 0.41 and a 200-day simple moving average of GBX 0.71. The stock has a market cap of £9.24 million, a P/E ratio of -0.09 and a beta of 0.42. The company has a debt-to-equity ratio of 370.22, a quick ratio of 2.80 and a current ratio of 0.68.

Oxford BioDynamics (LON:OBD) last posted its quarterly earnings data on Friday, February 28th. The biotechnology company reported GBX (4.50) (($0.06)) earnings per share for the quarter. Oxford BioDynamics had a negative return on equity of 289.38% and a negative net margin of 1,800.32%.

Oxford BioDynamics Company Profile

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.